Over time, cancer cells can develop resistance to BRAF inhibitors, rendering them less effective. This resistance can occur through various mechanisms, such as additional mutations in the MAPK/ERK pathway or activation of alternative signaling pathways that bypass the inhibited BRAF protein. Researchers are actively studying combination therapies to overcome resistance.
